(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 53.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Rhythm Pharmaceuticals's revenue in 2026 is $239,918,000.On average, 18 Wall Street analysts forecast RYTM's revenue for 2026 to be $20,992,311,281, with the lowest RYTM revenue forecast at $18,459,931,705, and the highest RYTM revenue forecast at $23,206,594,238. On average, 18 Wall Street analysts forecast RYTM's revenue for 2027 to be $38,144,741,949, with the lowest RYTM revenue forecast at $29,351,642,557, and the highest RYTM revenue forecast at $46,774,661,907.
In 2028, RYTM is forecast to generate $61,525,531,954 in revenue, with the lowest revenue forecast at $43,858,776,234 and the highest revenue forecast at $83,311,019,220.